SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Trinity Biotech plc and Certain Officers and Directors

NEW YORK--()--Levi & Korsinsky, LLP announces that it has commenced an investigation of Trinity Biotech plc (“Trinity” or the “Company”) (NASDAQ:TRIB) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On October 4, 2016, Trinity revealed that it was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer, following the U.S. Food and Drug Administration’s advice. Trinity also said it would decrease its spending by roughly 85%, to $1.5 million from $9 million each year, and that it would close its Swedish facility, eliminating 40 jobs. Following this news, Trinity stock dropped $6.53 per share, more than 50 percent, to close at $6.46 on October 4, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/trinity-biotech-trib

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq., 212-363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Release Summary

Levi & Korsinsky, LLP announces that it has commenced an investigation of Trinity Biotech plc concerning possible violations of federal securities laws

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq., 212-363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com